Context: Wide spread use of misoprostol is increasingly commoner in our obstetrics and gynaecological practice, most especially for Induction of labour in spite of its serious associated risks of maternal and fetal complications Objective: To determine the use of Misoprostol for induction of labour among the Obstetricians in the West African sub region. Results: About 91 % admit using misoprostol for IOL with only half (50%) having written protocols for labour induction with misoprostol. Almost all (93%) prefer the vaginal route for the administration of misoprostol and about 74% do not use misoprostol for those with Caesarean section scar compared to only 19% who do. Misoprostol is used for cervical ripening and control of post partum haemorrhage among 24.4% and 50% of the Obstetricians respectively. The commonest complications encountered were Fetal distress, uterine rupture and uterine hyper tonus among 54.8%, 52.4% and 45.2% of the respondents. Conclusions: Misoprostol use was high with yet serious complication occurring among those using it for IOL. Despite the manufacturers and other regulatory agents warning against its use in pregnancy because of serious maternal and fetal complications, misoprostol use for IOL is widespread. A regulated use of this drug especially in pregnancy is advocated.
INTRODUCTION
reports and meta analysis including Cochrane database, ACOG, British Royal college of Obstetrics and Gynaecology and other regulatory 4 agencies when used for IOL . Misoprostol compared to other induction agents is observed to be stable analogue, it can withstand tropical 5 conditions, hence does not need refrigeration . It s also cheap and easily available across the counter, and misoprostol may play an important role in Obstetrics and Gynaecology practice in poor resource settings like ours where maternal mortality is high and other prostaglandins 6 preparations are prohibitively expensive . For now "off" label use of misoprostol will continue Misoprostol is a synthetic prostaglandin E1analogue developed and marketed as Cytotec by GD, Searle Co, Chicago, IL for the treatment of gastric and duodenal ulcers as well as the 1 prevention of NSAIDS associated ulcers in 1985 . 2 The suggestion by Margulies that Misoprostol might be effective for labour induction generated interest that increased it's used in our Obstetrics and Gynaecological practice. Fifteen years after its introduction the manufacturers of the drug Searle pharmaceutical company warned against its use in pregnancy because of its arbotificient property and formally wrote a letter to the American College of Obstetrician and Gynaecologist (ACOG on august rd 23 2000 stressing on the dangers of this drug in pregnancy and its risks both to the mother and 3. fetus when used for induction of labour (IOL) In spite of the acceptable clinical evidence of other induction agent (Pitocin), wide spread "off" label use of misoprostol became increasingly common among Obstetricians, in spite of its risks from in our hospitals until such a time when our regulatory agencies will approve/license its use for IOL. This study was undertaken to determine the protocol and use of misoprostol for IOL and associated feto-maternal complications among the Obstetricians in the West African sub region.
METHODS

During the October 2007
Faculty of Obstetrics and Gynaecology of the West African College of Surgeons (WACS) fellowship examination fourty two examiners spread across 22 training institutions were issued with structured questionnaires to determine the use of misoprostol for IOL in their respective institutions. Information pertaining to unit (written) protocol, type and source of misoprostol, the minimum and maximum dose relating to parity and routes of administration of the drug. Also information pertaining to the used of misoprostol in patient with previous caesarean section, and other indication of misoprostol use in our units were obtained. The data was analysed using SPSS statistical package version 11.0 and test of significance was determined using Chi square test. 18 compared to oral route, while Bartusevicius , in a randomised controlled trial observed that sublingual 25ug and vaginal route 50ug has similar efficacy. Significant number of our obstetrician 66.8% prefer to commence IOL for primigravidae with 50ug compared to 19% who commenced with 25ug, but there was no much significant difference between those that use 25ug (42.9%) and 50ug(50%) for IOL in Multipara. Though there was no clear safety advantage, Sanchez had earlier reported that 50ug is more efficacious than 19 25ug tablet . It is worth noting that misoprostol (synthetic prostaglandin E1 analogue) is available in 200ug tablets and smaller doses are obtained by breaking into pieces which may not be accurate. The study also reports that the decision for the use of misoprostol for IOL was taken at the consultant level (59.5%) as against 2.4% at the level of the resident, while in about 38% the decision could be taken at either level. reported from many studies . Use of misoprostol for IOL may not be better substitute for Oxytocin infusion neither is it better than membrane sweeping or Foleys catheter for ripening of cervix if this complications are put into 22, 23 perspective . Use of misoprostol as single agent for cervical ripening is also common, 24.4% compared to 33.3% for misoprostol with Foleys catheter, 31% misoprostol with membrane sweeping, while Foleys catheter alone is only used by less than 10% of the respondents. Digital stretching of fetal membrane for cervical ripening is a common practice although largely 22 unreported . The ease of administration, availability low cost, and its efficacy despite disastrous consequences may be the main motivation for its widespread use. Fifty percent of the respondents also use this drug for the control of postpartum haemorrhage, while about 26% use it for PPH and incomplete abortion. However use of misoprostol in abortion related condition is very low, this is a surprise finding. It is a well known fact that pregnancy termination in most countries is illegal except where the mother's life is in danger or the fetus not viable or has major congenital abnormality. The observed low incidence for pregnancy termination may therefore be an under reporting. Further most recent survey by IPAS (Nigeria) of major pharmaceuticals outlets indicate that some of the drugs are probably dispensed without 24 prescription . All the respondents recorded some major complications associated with misoprostol use as highlighted by the manufacturers. This is a major source of concern. Maternal and fetal death and ruptured uterus are particularly worrisome. Since this drug is not available in smaller dosage preparation, it's usually broken into pieces to approximate the doses. This is also another set back for its use in ripening of the cervix and IOL especially that incidences of complications increases with dosage. It is absolutely necessary that this drugs are available in smaller doses and its use strictly regulated including close monitoring of patient after administration when use for ripening of the cervix and induction of labour.
RESULTS
Fourty two
Misoprostol is equally used for other indications
